The psoriasis area and severity index
is the adequate criterion to define severity in chronic plaque-type psoriasis.
Psoriasis area and severity index
50 as an endpoint in psoriasis trials: an unconvincing proposal.
These areas are also poorly represented in measures of skin severity, such as the Psoriasis Area and Severity Index
(PASI), and are usually not the focus of therapeutic clinical trials.
001 28 joints Psoriasis area and severity index
Mean age was 42 years, and mean Psoriasis Area and Severity Index
(PASI) was 12.
After the initial eight-week study, seven patients of 11, or 64%, showed a reduction in their psoriasis area and severity index
(PASI) score compared with their baseline PASI score at day one; three have remained stable and the PASI score has increased for one patient.
The primary end point was the reduction of the Psoriasis Area and Severity Index
(PASI) before and after treatment with Psoraxine.
After 12 weeks of treatment, both trials met the primary efficacy endpoint, which was the difference in the percentage of Xanelim-treated patients achieving a 75% or greater improvement in Psoriasis Area and Severity Index
(PASI) scores over placebo.
According to the company, results revealed that after 16 weeks of treatment, the product (150 mg) met the co-primary endpoints of around 90% improvement in the psoriasis area and severity index
(PASI 90) and a static physician global assessment (sPGA) score of clear or almost clear (sPGA 0/1) across all three studies compared with placebo or adalimumab (based on trial design).
At week 60, at least 80% of patients on maintenance therapy with ixekizumab achieved at least a 75% improvement in the Psoriasis Area and Severity Index
, and at least 73% were rated clear or almost clear (N Engl J Med.
The self-administered psoriasis area and severity index
is valid and reliable.